Computerized cognitive remediation therapy
Computerized cognitive remediation therapy has been studied in 3 papers since 2022: 3 trials in people; 2 in the past year. The newest paper, Jun 19, 2026: “A study on the effects of CCRT on cognitive function and blood biomarkers in community-dwelling older adults with MCI”.
3 papers study it3 findingsUpdated
See all 3 papers on computerized cognitive remediation therapy
At a glance
The findings reach people, from one lab or study. 1 lab.
“intervention group showed significantly greater improvements in MMSE and MoCA total scores compared to the control group”
None of its findings points the other way.
- 1 lab
- Human trial3
Studies in people
1 study gave computerized cognitive remediation therapy to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Improves cognitive function down: Decreases GFAPP < 0.001 no change: Has no effect on P-TAU181P = 0.501 | Randomized trial12 weeks | 68 peopleOlder adults; Patient cohorts | BMC geriatrics, Jun 19, 2026 |
What did studies of computerized cognitive remediation therapy find?
3Studies of computerized cognitive remediation therapy measured 3 outcomes: P-TAU181, GFAP and cognitive function.
P-TAU181
no changein humans1
1 study
P-TAU181
no changein humans1
Computerized cognitive remediation therapy showed no clear effect on P-TAU181 in humans (P = 0.501).
“no significant difference was found in P-tau181 levels (P = 0.501)”
Human trial12 weeks
BMC geriatrics
GFAP
downin humans1
1 study
GFAP
downin humans1
Computerized cognitive remediation therapy decreases GFAP in humans (P < 0.001).
“Plasma GFAP levels significantly decreased in the intervention group compared to the control group (P < 0.001)”
Human trial12 weeks
BMC geriatrics
Cognitive function
upin humans1
1 study
Cognitive function
upin humans1
Computerized cognitive remediation therapy improves cognitive function in humans.
“intervention group showed significantly greater improvements in MMSE and MoCA total scores compared to the control group”
Human trial12 weeks
BMC geriatrics